Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVG-2089 in Immune Thrombocytopenia
2024-520359-26-00Phase 2Authorised
- Sponsor
- Nuvig Therapeutics
- Start
- Aug 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of NVG-2089 in immune thrombocytopenia (ITP), sponsored by Nuvig Therapeutics. Primary endpoint: Incidence, nature, and severity of TEAEs and SAEs. Planned start Aug 2025; status: authorised.
02
Drugs
NVG-2089
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-520359-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520359-26-00.